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Background: Laninamivir octanoate hydrate (laninamivir) is a
ong-acting neuraminidase inhibitor, which completes treatment
ith only a single dose. It was launched in October 2010 in Japan as
n anti-inﬂuenza agent. Since laninamivir was approved in Japan
or the ﬁrst time in the world, it is extremely important to elu-
idate the actual status of its efﬁcacy in clinical experiences. We
nvestigated the efﬁcacy of laninamivir during a postmarketing
urveillance conducted in the 2010/2011 inﬂuenza season.
Methods: A total of 3,732 patients diagnosed with inﬂuenza
nfections by use of a rapid inﬂuenza diagnostic kit at 787 hos-
itals around Japan were enrolled between November 2010 and
pril 2011 in this surveillance. Generally, patients under 10 years
ld inhaled a single dose of 20 mg as laninamivir, while patients at
0 or older inhaled a single dose of 40 mg. A diary-based investiga-
ionwasperformed to assess the efﬁcacyon thebasis of ‘time (days)
o fever resolution and ‘time(days) to relief of inﬂuenza symptoms.
he status of inhalation (whether patient could successfully inhale
aninamivir as instructed by doctors/pharmacists) was also inves-
igated.
Results: There were 3,524 patients eligible for efﬁcacy evalua-
ion. The median time to fever resolution in patients with type A
r B inﬂuenza infection was 3 days, including the day of inhalation.
he median time to symptom relief was 4 days. Based on attend-
ng physician’s judgment on efﬁcacy, the efﬁcacy rate was 97.6% in
ype A inﬂuenza, 93.3% in type B inﬂuenza, and 100% in mixed type
nﬂuenza. “Treatment failure”wasmost closely correlatedwith the
tatus of inhalation. “Unsatisfactory inhalation” or “inhalation fail-
re” was reported in about 5% among pediatric patients under 5
ears.
Conclusion: Laninamivirwas conﬁrmed to be an effective treat-
ent in more than 90% of patients with type A or type B inﬂuenza
nfections, even though this drug is an anti-inﬂuenza agent that
ompletes treatment with only a single inhalation. This drug was
onsidered to be useful for the treatment of inﬂuenza infections
ith respect to its convenience for use and the improvement of
ompliance.
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Japanese encephalitis in eastern Nepal: access to the laboratory
diagnosis
B. Khanal ∗, R.R. Singh, S.K. Bhattacharya
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Background: Japanese encephalitis (JE) is a signiﬁcant cause of
morbidity and mortality in Nepal. Conﬁrmation of JE among the
cases of Acute Encephalitis Syndrome (AES) is essential for estima-
tion of disease burden and national immunization strategy. New
initiative of JE surveillance national guidelines has utilized the
WHO/Immunization preventable disease (IPD) network to increase
the access of AES cases in peripheral hospitals to JE diagnosis.
Department ofMicrobiology, BPKoirala Institute ofHealth Sciences
(BPKIHS), remains the only centre outside the capital city to pro-
vide JE laboratory diagnosis.Objective of the present study was to
assess the access of peripheral hospitals to the JE diagnostic facility
and to determine the frequency of JE among the AES cases.
Methods: CSF and/or blood samples obtained from cases of AES
admitted in BPKIHS and the district hospitals and submitted to JE
laboratory from the year 2000 to 2011 were included. From the
peripheral hospitals samples were transported to laboratory by a
surveillance team of WHO/IPD. Specimens having anti-JE IgM (≥40
units); detected by IgM capture ELISA were conﬁrmed as positive
for JE virus infection. Diagnostic outcome report was provided to
the WHO/IPD network.
Results: A total of 3352 samples were received. Out of 3352
samples, 760 (22.9%) exhibited the presence of anti-JE antibody.
Positivity was lower in 2008 (12.1%) as compared to high-
est rate in 2001 (61.1%). Rate of percent positivity observed
was as follows; 2000(18.2), 2002(25.2), 2003(31.5), 2004(26.5),
2005(25.4), 2006(34.8), 2007(16.0) and 2009(17.1), 2010(14.6),
2011(14.1).More than two third of the specimens were from chil-
dren (<15yrs). Overall male predominance was observed. Samples
were obtained from >20 districts of Nepal.
Conclusion: JE continues to prevail in eastern Nepal. Due to uti-
lizationofWHO/IPDnetwork for the surveillance, diagnostic facility
has become accessible for the patients admitted in district hos-
pitals. As deﬁnitive diagnosis of JE was established only in 22.9%
among AES cases, exploring the etiological agents in 77% remains a
challenge. Recognized as the only referral JE diagnostic laboratory
outside the capital city, this centre,however, needs the upgrad-http://dx.doi.org/10.1016/j.ijid.2012.05.206
